U.S. markets closed

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1439-0.0083 (-5.45%)
At close: 3:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1522
Open0.1570
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1400 - 0.1625
52 Week Range0.0940 - 0.3100
Volume349,773
Avg. Volume610,593
Market Cap52.857M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1030
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis
    ACCESSWIRE

    Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis

    * Tetra strengthens its intellectual property portfolio * Approximately 12% of women may have early symptoms of Interstitial CystitisOTTAWA, ON / ACCESSWIRE / April 15, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announces the granting of a new patent from the United States Patent and Trademark Office for patent application number 16/190,450.

  • Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada
    ACCESSWIRE

    Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada

    * REDUVO would have Canada's only Drug Identification Number for a THC-based prescription drug * The addressable market is estimated to be $80M CDN by 2022OTTAWA, ON / ACCESSWIRE / April 14, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have advanced the REDUVO soft gel capsules New Drug Submission (NDS) file by responding to a request for more information from Health Canada, as previously announced on March 15, 2021.

  • FDA Provides Positive Feedback on Tetra Bio-Pharma's Application for ARDS-003 Clinical Development in COVID-19 Patients
    ACCESSWIRE

    FDA Provides Positive Feedback on Tetra Bio-Pharma's Application for ARDS-003 Clinical Development in COVID-19 Patients

    * FDA acknowledged that the preclinical safety data are acceptable to file an Investigational New Drug Application (IND) aimed at treating hospitalized COVID-19 patients at risk of developing ARDSOTTAWA, ON / ACCESSWIRE / April 5, 2021 /Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development is pleased to announce that the U.